Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Alterity Therapeutics (PRAN) News Today

Alterity Therapeutics logo

PRAN Latest News

ATHE Alterity Therapeutics Limited - Seeking Alpha
Alterity Therapeutics Reveals Top Option Holders
Alterity Therapeutics completes placement
Alterity Therapeutics announces regulatory notice
Alterity Therapeutics Ltd PBN
Alterity Therapeutics to List New Securities on ASX
Alterity Therapeutics raises A$40M in placement
Alterity Therapeutics price target raised to $12 from $8 at Maxim
Alterity Therapeutics Ltd (ADR) trading halted, news pending
Alterity Therapeutics reports cash balance of A$4.54M as of December 31
Alterity CEO says ‘filled with optimism for 2025’
Alterity Therapeutics Alerts Investors on Potential Risks
Alterity Therapeutics Advances Amid Successful AGM
Alterity Therapeutics Advances in Neurodegenerative Drug Trials
Alterity Therapeutics Appoints New Company Secretary
Alterity Therapeutics appoints Abby Macnish Niven as secretary
Alterity Therapeutics Unveils New Advances for MSA Tracking
Alterity Therapeutics announces new publication on ATH434
Alterity Therapeutics: Innovative Approach with ATH434
Alterity Therapeutics Reveals Positive MSA Trial Data
Alterity Therapeutics Prepares for 2024 Annual General Meeting
Kazia Therapeutics Limited (KZIA)
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
Why Is Alterity Therapeutics (ATHE) Stock Up 150% Today?
Axsome Therapeutics Inc AXSM
Get Alterity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRAN Media Mentions By Week

PRAN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PRAN
News Sentiment

0.00

1.12

Average
Medical
News Sentiment

PRAN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PRAN Articles
This Week

0

0

PRAN Articles
Average Week

Get the Latest News and Ratings for PRAN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alterity Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:PRAN) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners